Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033
상품코드:1470315
리서치사:The Business Research Company
발행일:2024년 04월
페이지 정보:영문 279 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 단클론항체(mAbs) 시장 규모는 2018년 1,151억 450만 달러로 평가되었고 2023년까지 복합 연간 성장률(CAGR) 12.0% 이상으로 성장할 것으로 예측됩니다.
연구개발비 증가
신약의 연구개발에 대한 세계 바이오의약품 지출 증가가 이 기간 시장 성장에 기여했습니다. 서유럽 국가의 규제 부담 증가와 비용 억제 강화로 기업 연구개발의 초점은 암이나 희소질환 등 투자대효과가 높은 질환에 대한 의약품 및 치료제 개발로 옮겨갔습니다. 전임상시험부터 승인까지의 바이오의약품기업의 연구개발비 중 바이오의약품 시장 성공에 필요한 프로세스 개발과 제조에 할당되는 비용의 비율은 1단계에서 13-17%, 승인 성공률은 4 -30%와 편차가 있는 것을 알았습니다. 최근 항체 전체의 성공률이 22%인 경우 연구개발에 대한 CMC 비용의 기여율은 17%를 나타낼 전망이며 결정되었습니다. 따라서 의약품의 R&D 비용 증가는 R&D 활동에 대한 투자와 자금 증가로 이어져 단일클론 항체 시장을 촉진시켰습니다.
목차
제1장 주요 요약
단클론항체(mAbs) - 시장의 매력과 거시경제 상황
제2장 목차
제3장 표제 목록
제4장 도표 일람
제5장 보고서 구성
제6장 시장 특징
일반적인 시장의 정의
개요
단클론항체(mAbs) 시장 정의와 세분화
시장 세분화 : 공급원별
마우스
키메라
인간화
인간
시장 세분화 : 용도별
항암제
면역학적
감염증
혈액 질환
기타 용도
시장 세분화 : 최종 사용자별
병원
전문센터
기타 최종 사용자
제7장 주요 시장 동향
표적요법과 병용요법에 대한 투자
시장에서의 혁신과 확대를 추진하기 위한 시장기업간의 전략적 파트너십과 콜라보레이션
치료에 혁명을 일으키는 연구개발 투자
혁신을 가속화하기 위한 인공지능의 통합
신규 치료법과 바이오시밀러의 제품 혁신에 의한 치료 옵션의 확산
제8장 단클론항체(mAbs) 시장 - 거시경제 시나리오
COVID-19가 단클론항체(mAbs) 시장에 미치는 영향
우크라이나 전쟁이 단클론항체(mAbs) 시장에 미치는 영향
고인플레이션이 단클론항체(mAbs) 시장에 미치는 영향
제9장 시장 규모와 성장
시장 규모
시장 성장 실적(2018년-2023년)
시장 성장 촉진요인(2018년-2023년)
시장 성장 억제요인(2018년-2023년)
시장 성장 예측(2023년-2028년, 2033년)
시장 성장 촉진요인(2023년-2028년)
시장 성장 억제요인(2023년-2028년)
제10장 세계 단클론항체(mAbs) 시장 세분화
세계 단클론항체(mAbs) 시장 : 공급원별, 실적과 예측(2018년-2023년, 2028년, 2033년)
세계 단클론항체(mAbs) 시장 : 용도별, 실적과 예측(2018년-2023년, 2028년, 2033년)
세계 단클론항체(mAbs) 시장 : 최종 사용자별, 실적과 예측(2018년-2023년, 2028년, 2033년)
제11장 단클론항체(mAbs) 시장 : 지역별 및 국가별 분석
세계 단클론항체(mAbs) 시장 :지역별, 실적과 예측(2018년-2023년, 2028년, 2033년)
세계 단클론항체(mAbs) 시장 : 국가별, 실적과 예측(2018년-2023년, 2028년, 2033년)
Exelixis Inc. Acquired Gamamabs Pharma SA's AMHR2 Antibody Technology
Sanofi Acquired Kymab Group Ltd.
Boehringer Ingelheim Acquired Preclinical Antibody Pipeline From Northern Biologics Inc.
Servier Acquired Symphogen A/S
Gilead Sciences Acquired Forty Seven
True North Acquired Stake In Biocon Biologics
제21장 파이프라인 분석
제22장 기회와 전략
2028년 세계 단클론항체(mAbs) 시장 - 가장 새로운 기회를 제공하는 국가
2028년 세계 단클론항체(mAbs) 시장 - 가장 새로운 기회를 제공하는 부문
2028년 세계 단클론항체(mAbs) 시장 - 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제23장 단클론항체 시장 : 결론 및 제안
결론
추천 사항
제품
장소
가격
프로모션
사람들
제24장 부록
BJH
영문 목차
영문목차
Monoclonal antibodies (mAbs) are laboratory-produced antibodies that specifically bind to target molecules with high affinity, avidity and specificity. This binding results in inhibition of the target molecule's biological function by blocking its interaction with other receptor proteins or directing its destruction and elimination.
The monoclonal antibodies (mAbs) market consists of sales by entities (organizations, sole traders and partnerships), that produce monoclonal antibodies used to treat various medical conditions including cancer, inflammatory and autoimmune diseases.
The global monoclonal antibodies (mAbs) market was valued at $115,104.5 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 12.0%.
Increase In R&D Expenditure
The growth in global biopharmaceutical spending on research and development of new drugs contributed to the growth of the market during this period. The increased regulatory burden and greater cost containment in western countries led to shift in companies R&D focus to the development of drugs and therapeutics for diseases such as cancer and rare diseases with high return on investment. The percentage of a biopharmaceutical company's R&D out-of-pocket costs from pre-clinical to approval that needs to be allocated to process development and manufacturing for each biopharmaceutical market success was found to vary between 13-17% for Phase I to approval success rates of 4-30%. For the most recent antibody overall success rates of 22%, the CMC cost contribution to R&D was determined as 17%. Therefore, an increase in pharmaceutical R&D expenditure leads to increasing investments and funding for the R&D activities, which drove the monoclonal antibodies market.
Investment in Targeted and Combination Therapy
Companies in the monoclonal antibodies (mAbs) market are investing in targeted and combination therapy, which has been proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. For instance, in September 2022, the European Union (EU) granted approval for AstraZeneca's Evusheld (comprising tixagevimab and cilgavimab, previously known as AZD7442). This long-acting antibody combination was authorized for treating COVID-19 in adults and adolescents (aged 12 years and older, weighing at least 40 kg) who do not need supplemental oxygen and face an elevated risk of developing severe COVID-19. Also, in January 2020, European Commission has granted conditional marketing authorization for Polivy(R) (polatuzumab vedotin), in combination with bendamustine plus MabThera(R) (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma.
The global monoclonal antibodies (mAbs) market is concentrated, with a few large player operating in the market. The top ten competitors in the market made up 41.8% of the total market in 2022.
Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global monoclonal antibodies (mAbs) market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies based on local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Where is the largest and fastest-growing market for monoclonal antibodies (mAbs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The monoclonal antibodies (mAbs) market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider monoclonal antibodies (mAbs) market; and compares it with other markets.
The report covers the following chapters:
Introduction And Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by source, by application and by end-users market.
Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the monoclonal antibodies (mAbs) market.
Global Market Size and Growth - Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional And Country Analysis - Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
Market Segmentation - Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by source, by application and by end-users in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
Regional Market Size And Growth - Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Key Mergers And Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for monoclonal antibodies (mAbs) providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Scope
Markets Covered:
1) By Source: Murine; Chimeric; Humanized; Human
2) By Application: Anti-Cancer; Immunological; Infectious Diseases; Hematological Disease; Other Applications
3) By End-Users: Hospitals; Specialty Centers; Other End-Users
Companies Mentioned: Johnson & Johnson Inc.; Merck & Co., Inc.; F. Hoffman-La Roche Ltd.; Bristol Myers Squibb; GlaxoSmithKline plc
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; monoclonal antibodies (mAbs) indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
10 Global Monoclonal Antibodies (mAbs) Market Segmentation
10.1 Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.2 Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.3 Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
11 Monoclonal Antibodies (mAbs) Market, Regional and Country Analysis
11.1 Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
11.2 Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12 Asia-Pacific Market
12.1 Summary
12.1.1 Market Overview
12.1.2 Region Information
12.1.3 Market Information
12.1.4 Background Information
12.1.5 Government Initiatives
12.1.6 Regulations
12.1.7 Regulatory Bodies
12.1.8 Major Associations
12.1.9 Taxes Levied
12.1.10 Corporate Tax Structure
12.1.11 Investments
12.1.12 Major Companies
12.2 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.3 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.4 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.5 Asia-Pacific Monoclonal Antibodies (mAbs) Market: Country Analysis
12.6 China Market
12.7 Summary
12.7.1 Market Overview
12.7.2 Country Information
12.7.3 Market Information
12.7.4 Background Information
12.7.5 Government Initiatives
12.7.6 Regulations
12.7.7 Regulatory Bodies
12.7.8 Major Associations
12.7.9 Taxes Levied
12.7.10 Corporate Tax Structure
12.7.11 Investments
12.7.12 Major Companies
12.8 China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.9 China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.10 China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.11 India Market
12.12 India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.13 India Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.14 India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.15 Japan Market
12.16 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.17 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.18 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.19 Australia Market
12.20 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.21 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.22 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.23 Indonesia Market
12.24 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.25 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.26 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.27 South Korea Market
12.28 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.29 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.30 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13 Western Europe Market
13.1 Summary
13.1.1 Market Overview
13.1.2 Region Information
13.1.3 Market Information
13.1.4 Background Information
13.1.5 Government Initiatives
13.1.6 Regulations
13.1.7 Regulatory Bodies
13.1.8 Major Associations
13.1.9 Taxes Levied
13.1.10 Corporate tax structure
13.1.11 Investments
13.1.12 Major Companies
13.2 Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.3 Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.4 Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.5 Western Europe Monoclonal Antibodies (mAbs) Market: Country Analysis
13.6 UK Market
13.7 UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.8 UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.9 UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.10 Germany Market
13.11 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.12 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.13 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.14 France Market
13.15 France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.16 France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.17 France Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14 Eastern Europe Market
14.1 Summary
14.1.1 Market Overview
14.1.2 Region Information
14.1.3 Market Information
14.1.4 Background Information
14.1.5 Government Initiatives
14.1.6 Regulations
14.1.7 Regulatory Bodies
14.1.8 Major Associations
14.1.9 Taxes Levied
14.1.10 Corporate Tax Structure
14.1.11 Investments
14.1.12 Major Companies
14.2 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.3 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.4 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.5 Eastern Europe Monoclonal Antibodies (mAbs) Market: Country Analysis
14.6 Russia Market
14.7 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.8 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.9 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15 North America Market
15.1 Summary
15.1.1 Market Overview
15.1.2 Region Information
15.1.3 Market Information
15.1.4 Background Information
15.1.5 Government Initiatives
15.1.6 Regulations
15.1.7 Regulatory Bodies
15.1.8 Major Associations
15.1.9 Taxes Levied
15.1.10 Corporate Tax Structure
15.1.11 Investments
15.1.12 Major Companies
15.2 North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.3 North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.4 North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.5 North America Monoclonal Antibodies (mAbs) Market: Country Analysis
15.6 USA Market
15.7 Summary
15.7.1 Market Overview
15.7.2 Country Information
15.7.3 Market Information
15.7.4 Background Information
15.7.5 Government Initiatives
15.7.6 Regulations
15.7.7 Regulatory Bodies
15.7.8 Major Associations
15.7.9 Taxes Levied
15.7.10 Corporate Tax Structure
15.7.11 Investments
15.7.12 Major Companies
15.8 USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.9 USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.10 USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16 South America Market
16.1 Summary
16.1.1 Market Overview
16.1.2 Region Information
16.1.3 Market Information
16.1.4 Background Information
16.1.5 Government Initiatives
16.1.6 Regulations
16.1.7 Regulatory Bodies
16.1.8 Major Associations
16.1.9 Taxes Levied
16.1.10 Corporate Tax Structure
16.1.11 Investments
16.1.12 Major Companies
16.2 South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.3 South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.4 South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.5 South America Monoclonal Antibodies (mAbs) Market: Country Analysis
16.6 Brazil Market
16.7 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.8 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.9 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
17 Middle East Market
17.1 Summary
17.1.1 Market Overview
17.1.2 Region Information
17.1.3 Market Information
17.1.4 Background Information
17.1.5 Government Initiatives
17.1.6 Regulations
17.1.7 Regulatory Bodies
17.1.8 Major Associations
17.1.9 Taxes Levied
17.1.10 Corporate Tax Structure
17.1.11 Investments
17.1.12 Major Companies
17.2 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
17.3 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
17.4 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
18 Africa Market
18.1 Summary
18.1.1 Market Overview
18.1.2 Region Information
18.1.3 Market Information
18.1.4 Background Information
18.1.5 Government Initiatives
18.1.6 Regulations
18.1.7 Regulatory Bodies
18.1.8 Major Associations
18.1.9 Taxes Levied
18.1.10 Corporate Tax Structure
18.1.11 Investment
18.1.12 Major Companies
18.2 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
18.3 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
18.4 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
